Nephros Inc (NEPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nephros Inc stock (NEPH) is currently trading at $3.05. Nephros Inc PE ratio is 28.27. Nephros Inc PS ratio (Price-to-Sales) is 1.76. Analyst consensus price target for NEPH is $7.00. WallStSmart rates NEPH as Sell.
- NEPH PE ratio analysis and historical PE chart
- NEPH PS ratio (Price-to-Sales) history and trend
- NEPH intrinsic value — DCF, Graham Number, EPV models
- NEPH stock price prediction 2025 2026 2027 2028 2029 2030
- NEPH fair value vs current price
- NEPH insider transactions and insider buying
- Is NEPH undervalued or overvalued?
- Nephros Inc financial analysis — revenue, earnings, cash flow
- NEPH Piotroski F-Score and Altman Z-Score
- NEPH analyst price target and Smart Rating
Nephros Inc
📊 No data available
Try selecting a different time range
NEPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Nephros Inc (NEPH)
NEPH trades 439% above its Graham fair value of $0.75, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Nephros Inc (NEPH) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Nephros Inc (NEPH) Key Strengths (2)
Paying $1.76 for every $1 of annual revenue
Strong revenue growth at 22.20% annually
Supporting Valuation Data
Nephros Inc (NEPH) Areas to Watch (7)
Earnings declining -82.40%, profits shrinking
Near-zero operating margins, business under pressure
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.1x book value
Thin profit margins with limited profitability
Moderate profitability with room for improvement
Moderate institutional interest at 49.82%
Supporting Valuation Data
Nephros Inc (NEPH) Detailed Analysis Report
Overall Assessment
This company scores 40/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (1.76) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 22.20%.
The Bear Case
The primary concerns are EPS Growth, Operating Margin, Market Cap. Some valuation metrics including Price/Book (3.06) suggest expensive pricing. Growth concerns include EPS Growth at -82.40%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.70%, Operating Margin at 0.38%, Profit Margin at 6.36%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 22.20% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. EPS Growth and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NEPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NEPH's Price-to-Sales ratio of 1.76x trades at a deep discount to its historical average of 3.78x (48th percentile). The current valuation is 91% below its historical high of 18.95x set in Dec 2019, and 96% above its historical low of 0.9x in Mar 2019. Over the past 12 months, the PS ratio has expanded from ~1.3x, reflecting growing market expectations outpacing revenue growth.
Compare NEPH with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Nephros Inc (NEPH) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
Nephros Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 19M with 22% growth year-over-year. Profit margins are thin at 6.4%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 230,000 in free cash flow and 230,000 in operating cash flow. Earnings are translating into actual cash generation.
Earnings fell 82% YoY while revenue grew 22%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can Nephros Inc push profit margins above 15% as the business scales?
Growth sustainability: can Nephros Inc maintain 22%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact Nephros Inc.
Bottom Line
Nephros Inc offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(2 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:12:49 AM
About Nephros Inc(NEPH)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.